Lipoprotein(a) Blood Test: Normal Ranges, Causes & What Your Results Mean

What Is Lipoprotein(a)?

Lipoprotein(a) — commonly written as Lp(a) and pronounced "L-P-little-a" — is a type of lipoprotein particle found in the blood. It is structurally similar to low-density lipoprotein (LDL) cholesterol but has an additional protein called apolipoprotein(a) attached to its surface. This unique protein gives Lp(a) properties that make it particularly harmful to cardiovascular health.

Lp(a) levels are overwhelmingly determined by genetics. Unlike LDL cholesterol or triglycerides, your Lp(a) concentration is largely set at birth by the LPA gene and remains relatively stable throughout your life. Diet, exercise, and most conventional lipid-lowering medications have minimal impact on Lp(a) levels, which is why it has historically been under-tested despite its significant contribution to cardiovascular risk.

Lp(a) promotes atherosclerosis through three interconnected mechanisms: it deposits cholesterol into artery walls (like LDL), it carries oxidised phospholipids that trigger inflammation, and its apolipoprotein(a) component inhibits fibrinolysis (the body's natural clot-dissolving process), promoting thrombosis. This triple threat makes elevated Lp(a) one of the strongest independent genetic risk factors for heart attack, stroke, and aortic valve stenosis.

Approximately one in five people worldwide has elevated Lp(a). In the UK, this translates to over 13 million individuals — most of whom have never been tested.

Why Is Lp(a) Tested?

Growing recognition of Lp(a) as a major cardiovascular risk factor has led several guidelines — including the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) — to recommend that every adult should have Lp(a) measured at least once in their lifetime. Specific reasons for testing include:

• Family history of premature cardiovascular disease: If a first-degree relative had a heart attack or stroke before age 55 (men) or 65 (women), Lp(a) should be measured.
• Personal history of cardiovascular events: Patients who have had a heart attack, stroke, or peripheral arterial disease, especially at a young age or with well-controlled conventional risk factors.
• Familial hypercholesterolaemia (FH): Lp(a) is frequently elevated in FH patients and contributes to their excess cardiovascular risk beyond LDL cholesterol.
• Unexplained LDL elevation: Lp(a) contains cholesterol and can contribute to total LDL measurements. Standard lipid panels may overestimate true LDL if Lp(a) is high.
• Aortic valve stenosis: Elevated Lp(a) is a causal risk factor for calcific aortic valve disease, particularly in younger patients.
• Risk reclassification: When standard risk calculators place a patient in a borderline or intermediate risk category, an elevated Lp(a) can reclassify them to a higher risk group, potentially changing management.
• Recurrent cardiovascular events despite optimal therapy: Patients who experience events despite statins and other treatments may have residual risk driven by Lp(a).

Normal Ranges

Lp(a) can be measured in either mass concentration (mg/dL) or molar concentration (nmol/L). The two scales are not directly interconvertible because the apolipoprotein(a) protein varies in size between individuals. Nmol/L is increasingly preferred as it is more standardised. The table below shows commonly used thresholds:

Risk Category	Lp(a) Level (nmol/L)	Lp(a) Level (mg/dL)	Interpretation
Desirable	< 75 nmol/L	< 30 mg/dL	Low cardiovascular risk from Lp(a)
Borderline / Moderate risk	75–125 nmol/L	30–50 mg/dL	Mildly elevated; consider other risk factors
High risk	> 125 nmol/L	> 50 mg/dL	Significantly elevated cardiovascular risk
Very high risk	> 250 nmol/L	> 100 mg/dL	Markedly elevated; aggressive risk management

The ESC/EAS guidelines highlight that Lp(a) above 125 nmol/L (approximately 50 mg/dL) confers a cardiovascular risk equivalent to heterozygous familial hypercholesterolaemia. Because Lp(a) is genetically determined, a single measurement is generally sufficient — repeat testing is only needed if a specific intervention is being monitored.

What Do High Lp(a) Levels Mean?

Elevated Lp(a) is almost always genetic in origin, but certain conditions can further raise levels or amplify risk:

• Genetic inheritance: The primary determinant. Lp(a) levels are 80–90% heritable, controlled by the LPA gene on chromosome 6. Certain ethnic groups, particularly people of African descent, tend to have higher average Lp(a) levels.
• Familial hypercholesterolaemia: Many FH patients have concomitantly high Lp(a), which contributes to their excess cardiovascular risk.
• Chronic kidney disease: Impaired renal clearance can increase Lp(a) levels, and this is thought to contribute to the high cardiovascular mortality in CKD patients.
• Nephrotic syndrome: Increased hepatic lipoprotein synthesis, triggered by urinary protein loss, raises Lp(a).
• Hypothyroidism: Untreated hypothyroidism is associated with mildly elevated Lp(a). Treatment with levothyroxine may partially normalise levels.
• Menopause and oestrogen decline: Lp(a) levels tend to rise after menopause, possibly contributing to the increased cardiovascular risk in postmenopausal women.
• Inflammatory states: Lp(a) is an acute-phase reactant and can rise transiently during infection or systemic inflammation.

What Do Low Lp(a) Levels Mean?

Low Lp(a) is generally favourable from a cardiovascular perspective. Here is what different low-range results imply:

• Below 30 nmol/L: Indicates very low genetic production of Lp(a). This is associated with the lowest Lp(a)-attributable cardiovascular risk and is entirely normal.
• 30–75 nmol/L: Within the desirable range. No clinical concern.
• Hyperthyroidism: Overactive thyroid function can reduce Lp(a) levels. If Lp(a) is unexpectedly low, thyroid function should be checked.
• Oestrogen therapy: Hormone replacement therapy (HRT) and oral contraceptives containing oestrogen can lower Lp(a) by 20–30%. This is one of the few interventions shown to meaningfully reduce levels.
• Niacin (vitamin B3) use: High-dose niacin can reduce Lp(a) by 20–30%, though it is rarely used in UK clinical practice due to side effects.
• Liver disease: Severe hepatic impairment reduces lipoprotein production, which can lower Lp(a) along with other lipoproteins.

There is no known clinical condition caused by Lp(a) deficiency. Very low or undetectable Lp(a) levels carry no adverse health consequences.

How to Improve Your Lp(a) Levels

Managing elevated Lp(a) is challenging because lifestyle changes have minimal effect on this genetically determined biomarker. The focus is on reducing overall cardiovascular risk rather than lowering Lp(a) itself:

Cardiovascular Risk Reduction

• Optimise LDL cholesterol: Since you cannot meaningfully lower Lp(a) through lifestyle or most medications, aggressively managing modifiable risk factors becomes paramount. Statins, ezetimibe, and PCSK9 inhibitors can substantially lower LDL cholesterol. ESC guidelines suggest that patients with elevated Lp(a) should aim for even lower LDL targets.
• Control blood pressure: Aim for below 130/80 mmHg, especially if you have elevated Lp(a). Even small reductions in blood pressure significantly reduce cardiovascular events.
• Manage diabetes: Optimal glycaemic control reduces the compounding cardiovascular risk in those with high Lp(a).
• Stop smoking: Smoking cessation is the single most impactful lifestyle change for cardiovascular risk reduction.
• Regular exercise: At least 150 minutes of moderate-intensity aerobic activity per week, as recommended by the NHS.
• Heart-healthy diet: A Mediterranean-style diet rich in fruits, vegetables, wholegrains, oily fish, nuts, and olive oil supports cardiovascular health.

Emerging Therapies

• Antisense oligonucleotides (ASOs): Pelacarsen, an ASO targeting hepatic Lp(a) production, has shown reductions of up to 80% in clinical trials. The HORIZON phase III outcomes trial is expected to report results soon and may transform Lp(a) management.
• Small interfering RNA (siRNA): Olpasiran and other siRNA therapies can reduce Lp(a) by over 95% in early-phase trials. These are administered as infrequent injections (every 3–6 months).
• PCSK9 inhibitors: Evolocumab and alirocumab reduce Lp(a) by approximately 20–30% as a secondary effect. They are primarily prescribed for LDL lowering but offer modest Lp(a) benefit.

What Does Not Work

• Diet and exercise: Have negligible effect on Lp(a) levels (though they benefit overall cardiovascular health).
• Statins: May slightly increase Lp(a) in some patients, though the net cardiovascular benefit of statins far outweighs this effect.
• Supplements: No over-the-counter supplement has been convincingly shown to lower Lp(a) in rigorous clinical trials.

When Should You Get Tested?

Given that Lp(a) is genetically determined and largely stable over a lifetime, the ESC recommends measuring it at least once in every adult. You should prioritise testing if:

• You have a family history of premature heart disease or stroke.
• You have been diagnosed with familial hypercholesterolaemia.
• You have had a heart attack, stroke, or peripheral vascular disease — especially at a young age.
• Your LDL cholesterol is higher than expected for your diet and lifestyle.
• You have aortic valve stenosis, particularly if diagnosed before age 60.
• You have recurrent cardiovascular events despite optimal statin therapy.
• You want a comprehensive understanding of your cardiovascular risk profile.
• You have chronic kidney disease or nephrotic syndrome.

Since Lp(a) levels are genetically fixed, repeat testing is generally unnecessary unless you are monitoring a specific treatment.

Which Lola Health Tests Include Lipoprotein(a)?

Lp(a) is increasingly recognised as an essential component of cardiovascular risk assessment. Lola Health includes Lp(a) in our advanced testing panels:

• Peak Insights — our most comprehensive health screen, including Lp(a) alongside a full lipid profile and over 50 other biomarkers for a complete cardiovascular risk assessment.
• Vital Check — a thorough wellness panel covering cardiovascular, metabolic, and hormonal health markers.
• Core Health — an essential health check providing key cardiovascular and metabolic insights.

All Lola Health tests use venous blood draws for clinical-grade accuracy. Your results are reviewed by qualified healthcare professionals who provide personalised recommendations based on your complete risk profile.